Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 21:00:00 28/05/2024 BST			5-day change	1st Jan Change
13.32 ^USD	+17.15%		+36.90%	+8.82%

05-20	Pulse Biosciences Moves New Record Date for Rights Offering	MT
05-14	Pulse Biosciences Appoints Burke Barrett as President, CEO	MT

Pulse Biosciences, Inc. Announces Resignation of Thomas J. Fogarty from the Board of Directors

December 19, 2019 at 09:03 pm

Pulse Biosciences, Inc. announced that Thomas J. Fogarty, M.D., resigned from the Board of Directors and all committees of the Board for personal reasons. The resignation of Mr. Fogarty is effective immediately.

Latest news about Pulse Biosciences, Inc.

Pulse Biosciences Moves New Record Date for Rights Offering	05-20	MT
Pulse Biosciences Appoints Burke Barrett as President, CEO	05-14	MT
Pulse Biosciences, Inc Announces CEO Changes	05-14	CI
Pulse Biosciences, Inc Announces Executive Changes	05-14	CI
Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System	05-09	CI
Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Sector Update: Health Care Stocks Slide Late Afternoon	04-01	MT
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	04-01	MT
Transcript : Pulse Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024	03-28
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-28	CI
Sector Update: Health Care Stocks Ease Late Afternoon	03-08	MT
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	03-08	MT
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	03-08	CI
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	02-14	CI
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	01-02	MT
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	01-02	MT
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	01-02	CI
Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter	12-20	CI
Pulse Biosciences Insider Bought Shares Worth $843,504, According to a Recent SEC Filing	12-14	MT
Pulse Biosciences Insider Bought Shares Worth $1,117,085, According to a Recent SEC Filing	12-01	MT
Pulse Biosciences Up 16% on Product Updates, Potential Stock Purchases by Duggan	11-27	DJ
Pulse Biosciences Cleared to Start Catheter Ablation Feasibility Trial; Set to File Application for Cardiac Clamp; Shares Rise	11-27	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	11-21	MT

Chart Pulse Biosciences, Inc.

Duration

Period

More charts

Company Profile

Pulse Biosciences, Inc. is a bioelectric medicine company. The Companyâs proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Companyâs Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.

Sector

Advanced Medical Equipment & Technology

Calendar

06/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

	1st Jan change	Capi.
PULSE BIOSCIENCES, INC.	+8.82%	628M
THERMO FISHER SCIENTIFIC	+7.87%	223B
DANAHER CORPORATION	+11.83%	195B
INTUITIVE SURGICAL, INC.	+18.87%	144B
BOSTON SCIENTIFIC CORPORATION	+30.03%	111B
SIEMENS HEALTHINEERS AG	+2.32%	65.19B
EDWARDS LIFESCIENCES CORPORATION	+14.15%	53.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.68%	50.28B
AGILENT TECHNOLOGIES, INC.	+6.60%	44.15B
GE HEALTHCARE TECHNOLOGIES INC.	+1.85%	36.45B

Other Advanced Medical Equipment & Technology